Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees | Adolescent Medicine | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    Should marijuana be co-prescribed with opioids, when the latter are needed for pain?
    DAVID KELLER, M.D., M.S. | Retired internal medicine physician.
    These results imply that the liberalized prescribing of marijuana may result in decreased use of opioids, and hence, fewer subsequent opioid-related overdose events.

    Marijuana has demonstrated some mild analgesic effects, when compared with placebo in clinical studies, but has not been proven to relieve pain as effectively as opioids.

    Dangerous effects of opioid abuse, including fatal respiratory depression, result when patients exceed safe dosages in an attempt to get high, or experience the opioid "rush".

    Could this study's results be explained by the possibility that abuse-prone patients are satisfied with the less-dangerous marijuana "high", and therefore
    demand less opioid medication when legal marijuana is available?

    If so, perhaps marijuana could be co-prescribed with opioids, as prophylaxis to opioid abuse, when opioids are required to treat appropriate pain syndromes, after appropriate studies have been conducted.
    Original Investigation
    Health Care Policy and Law
    May 2018

    Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees

    Author Affiliations
    • 1Department of Health Management & Policy, University of Kentucky College of Public Health, Lexington
    • 2Department of Health Policy & Management, Emory University Rollins School of Public Health, Atlanta, Georgia
    • 3National Bureau of Economic Research (NBER), Cambridge, Massachusetts
    JAMA Intern Med. 2018;178(5):673-679. doi:10.1001/jamainternmed.2018.1007
    Key Points

    Question  Are medical and adult-use marijuana laws passed after 2010 associated with lower rates of opioid prescribing for Medicaid enrollees?

    Findings  In this population-based, cross-sectional study using the all-capture Medicaid prescription data for 2011 to 2016, medical marijuana laws and adult-use marijuana laws were associated with lower opioid prescribing rates (5.88% and 6.38% lower, respectively).

    Meaning  Medical and adult-use marijuana laws have the potential to lower opioid prescribing for Medicaid enrollees, a high-risk population for chronic pain, opioid use disorder, and opioid overdose, and marijuana liberalization may serve as a component of a comprehensive package to tackle the opioid epidemic.


    Importance  Overprescribing of opioids is considered a major driving force behind the opioid epidemic in the United States. Marijuana is one of the potential nonopioid alternatives that can relieve pain at a relatively lower risk of addiction and virtually no risk of overdose. Marijuana liberalization, including medical and adult-use marijuana laws, has made marijuana available to more Americans.

    Objective  To examine the association of state implementation of medical and adult-use marijuana laws with opioid prescribing rates and spending among Medicaid enrollees.

    Design, Setting, and Participants  This cross-sectional study used a quasi-experimental difference-in-differences design comparing opioid prescribing trends between states that started to implement medical and adult-use marijuana laws between 2011 and 2016 and the remaining states. This population-based study across the United States included all Medicaid fee-for-service and managed care enrollees, a high-risk population for chronic pain, opioid use disorder, and opioid overdose.

    Exposures  State implementation of medical and adult-use marijuana laws from 2011 to 2016.

    Main Outcomes and Measures  Opioid prescribing rate, measured as the number of opioid prescriptions covered by Medicaid on a quarterly, per-1000-Medicaid-enrollee basis.

    Results  State implementation of medical marijuana laws was associated with a 5.88% lower rate of opioid prescribing (95% CI, −11.55% to approximately −0.21%). Moreover, the implementation of adult-use marijuana laws, which all occurred in states with existing medical marijuana laws, was associated with a 6.38% lower rate of opioid prescribing (95% CI, −12.20% to approximately −0.56%).

    Conclusions and Relevance  The potential of marijuana liberalization to reduce the use and consequences of prescription opioids among Medicaid enrollees deserves consideration during the policy discussions about marijuana reform and the opioid epidemic.